The Sulforaphane Production System® in Avmacol Extra Strength (ES) supplies broccoli seed extract (glucoraphanin) and Myrosimax® (Active Myrosinase Enzyme) which helps promote sulforaphane production in your body. The investigators hypothesize that daily intake of Avmacol ES can decrease kidney disease progression rate and decrease markers of oxidative stress and inflammation in Chronic Kidney Disease (CKD) patients. They will test this hypothesis in a randomized, double-blind, placebo controlled Phase 2 clinical trial. This proposed study has been funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), R01 DK128677.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Longitudinal change in the scores
Timeframe: Seven timepoints per patient (baseline; month 1; month 2; month 3; month 4; month 5, and month 6)
Longitudinal change in the scores
Timeframe: Seven timepoints per patient (baseline; month 1; month 2; month 3; month 4; month 5, and month 6)
Longitudinal change in the scores
Timeframe: Seven timepoints per patient (baseline; month 1; month 2; month 3; month 4; month 5, and month 6)
Longitudinal change in both systolic and diastolic blood pressure
Timeframe: Four timepoints per patient (baseline, month 1, month 3, and month 6)
Longitudinal change in 8-isoprostane in plasma
Timeframe: Four timepoints per patient (baseline, month 1, month 3, and month 6)
Longitudinal change in 8-isoprostane in urine
Timeframe: Four timepoints per patient (baseline, month 1, month 3, and month 6)
Longitudinal change in urinary albumin
Timeframe: Four timepoints per patient (baseline, month 1, month 3, and month 6)
Longitudinal change in protein/creatinine ratio
Timeframe: Four timepoints per patient (baseline, month 1, month 3, and month 6)
Longitudinal change in plasma hydrogen sulfide
Timeframe: Four timepoints per patient (baseline, month 1, month 3, and month 6)
Longitudinal change in plasma interleukin-6
Timeframe: Four timepoints per patient (baseline, month 1, month 3, and month 6)
Longitudinal change in urine nephrin
Timeframe: Four timepoints per patient (baseline, month 1, month 3, and month 6)
Longitudinal change in messenger RNA (mRNA) levels of cytoprotective enzymes in peripheral blood mononuclear cells (PBMCs)
Timeframe: Four timepoints per patient (baseline, month 1, month 3, and month 6)
Longitudinal change in messenger RNA (mRNA) levels of heat shock proteins in peripheral blood mononuclear cells (PBMCs)
Timeframe: Four timepoints per patient (baseline, month 1, month 3, and month 6)
Longitudinal change in sodium as part of comprehensive metabolic panel (CMP)
Timeframe: Four timepoints per patient (baseline, month 1, month 3, and month 6)
Longitudinal change in potassium as part of comprehensive metabolic panel (CMP)
Timeframe: Four timepoints per patient (baseline, month 1, month 3, and month 6)
Longitudinal change in chloride as part of comprehensive metabolic panel (CMP)
Timeframe: Four timepoints per patient (baseline, month 1, month 3, and month 6)
Longitudinal change in carbon Dioxide as part of comprehensive metabolic panel (CMP)
Timeframe: Four timepoints per patient (baseline, month 1, month 3, and month 6)
Longitudinal change in anion Gap as part of comprehensive metabolic panel (CMP)
Timeframe: Four timepoints per patient (baseline, month 1, month 3, and month 6)
Longitudinal change in blood urea nitrogen as part of comprehensive metabolic panel (CMP)
Timeframe: Four timepoints per patient (baseline, month 1, month 3, and month 6)
Longitudinal change in creatinine as part of comprehensive metabolic panel (CMP)
Timeframe: Four timepoints per patient (baseline, month 1, month 3, and month 6)
Longitudinal change in estimated Glomerular Filtration Rate (eGFR) as part of comprehensive metabolic panel (CMP)
Timeframe: Four timepoints per patient (baseline, month 1, month 3, and month 6)
Longitudinal change in calcium as part of comprehensive metabolic panel (CMP)
Timeframe: Four timepoints per patient (baseline, month 1, month 3, and month 6)
Longitudinal change in total protein as part of comprehensive metabolic panel (CMP)
Timeframe: Four timepoints per patient (baseline, month 1, month 3, and month 6)
Longitudinal change in albumin as part of comprehensive metabolic panel (CMP)
Timeframe: Four timepoints per patient (baseline, month 1, month 3, and month 6)
Longitudinal change in total bilirubin as part of comprehensive metabolic panel (CMP)
Timeframe: Four timepoints per patient (baseline, month 1, month 3, and month 6)
Longitudinal change in aspartate transaminase (AST) as part of comprehensive metabolic panel (CMP)
Timeframe: Four timepoints per patient (baseline, month 1, month 3, and month 6)
Longitudinal change in alanine transaminase (ALT) as part of comprehensive metabolic panel (CMP)
Timeframe: Four timepoints per patient (baseline, month 1, month 3, and month 6)
Longitudinal change in alkaline phosphatase (ALP) as part of comprehensive metabolic panel (CMP)
Timeframe: Four timepoints per patient (baseline, month 1, month 3, and month 6)
Longitudinal change in phosphorus as part of comprehensive metabolic panel (CMP)
Timeframe: Four timepoints per patient (baseline, month 1, month 3, and month 6)
Longitudinal change in glucose as part of comprehensive metabolic panel (CMP)
Timeframe: Four timepoints per patient (baseline, month 1, month 3, and month 6)